Announced details
We have entered into a joint development agreement and are advancing a joint development program for Pegevongitide (AV-001).
A Canadian privately held clinical-stage biopharmaceutical company. Its headquarters and research facilities are in Toronto, Canada, and it also has an operating base in Raleigh, North Carolina, United States. Its representative is CEO Dr. Brian E. Jahns. Pegevongitide (AV-001) was discovered and researched at the Sunnybrook Research Institute at Sunnybrook Hospital in Toronto.
Kissimmee, Florida, United States (presentation venue: Gaylord Palms Resort & Convention Center)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Pegevongitide (Tie2 receptor agonist: AV-001) |
| Counterparty | Vasomune Therapeutics, Inc. |
| Counterparty overview | A Canadian privately held clinical-stage biopharmaceutical company. Its headquarters and research facilities are in Toronto, Canada, and it also has an operating base in Raleigh, North Carolina, United States. Its representative is CEO Dr. Brian E. Jahns. Pegevongitide (AV-001) was discovered and researched at the Sunnybrook Research Institute at Sunnybrook Hospital in Toronto. |
| Relationship with the Company | We have entered into a joint development agreement and are advancing a joint development program for Pegevongitide (AV-001). |
| Launch date | 4 August 2026 (scheduled; presentation date and time at MHSRS) |
| Applicable area | Combat-related injuries, Blast injuries, Burn injuries, ARDS caused by infectious diseases, Acute Respiratory Distress Syndrome (ARDS), Hemorrhagic shock, Trauma, Shock following severe burns |
| Location | Kissimmee, Florida, United States (presentation venue: Gaylord Palms Resort & Convention Center) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To present research findings at MHSRS and engage with researchers and clinicians involved in combat casualty care and military operational medicine.